NEA, Pfizer back Complexa in $62M series C round

Rare disease play Complexa Inc. (Pittsburgh, Pa.) raised $62 million in a series C round led by New Enterprise Associates and Pfizer Venture Investments. New investors Edmond de Rothschild Investment Partners and HBM Healthcare Investments also participated, as did existing investor JAFCO.

In early 2018, Complexa hopes to start a Phase II trial of its lead candidate, CXA-10, to treat focal segmental glomerulosclerosis (FSGS). Next half, it also plans to start a Phase II study of CXA-10 to treat pulmonary arterial hypertension (PAH). The therapy is a small molecule endogenous nitro-fatty acid (NFA) modulator of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) and nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB; NFKB1; p105; p50)...